Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to ...

The number of bird flu cases in Central Massachusetts is relatively low, compared to a swath of the state that runs from ...

I have started, scratched out and even abandoned the writing of this essay. I couldn’t do it. It wasn’t there. Didn’t feel it ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

Moderna (NASDAQ: MRNA) shares fell over 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy. The downgrade follows a series of negative revisions to ...

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...